SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Joseph E. Kiss, MD

Professor of Medicine; Dept. of Medicine; Div. of Hem/Onc

Medical Director, Hemapheresis and Blood Services, CBB/ITxM

Email: jkiss@itxm.org

Phone: 412-209-7320

Contact
Office: 3636 Blvd. of the Allies
Pittsburgh, PA 15213
 
Phone: 412-209-7320
Fax: 412-209-7325
E-mail: jkiss@itxm.org
Administrative Assistant:
Deborah Small
Address: 3636 Blvd of the Allies
Pittsburgh, PA 15213
Email: dsmall@itxm.org
Phone: 412-209-7320
Education and Training
Education
AB, Boston University, Boston, MA, 1974
M.D., Georgetown University, Washington, DC, 1978
Training
Internship, University of Pittsburgh, Pittsburgh, PA, 1979
Residency and Chief Resident/Residency, University of Pittsburgh, Pittsburgh, PA, 1982
Hematology/Oncology Fellowship, Hospital of the University of PA, Philadelphia,PA, 1985
Blood Banking Fellowship, Central Blood Bank of Pittsburgh, 1986
Research Interest
As a clinical investigator, Dr. Kiss has been the recipient of federal funding for the past 13 years as a member/grantee of several NHLBI-sponsored research programs, including the Transfusion Medicine Hemostasis/Thrombosis Clinical Trials Network (TMH-CTN), and REDS-II and III programs [REDS is an acronym for Retrovirus(REDS-II) or Recipient (REDS-III) Epidemiology in Donors Study], and through the RO1 award mechanism (STRIDE-Strategies to Reduce Iron Deficiency). His research interests include studies in thrombotic microangiopathies, particularly thrombotic thrombocytopenic purpura (TTP). He served as protocol lead/PI on the multicenter Study of TTP and Rituximab (STAR) trial in 2009. Although the trial was closed early, the study was innovative in its design to utilize immunotherapy (rituximab) up front in a randomized controlled trial in acquired (autoimmune) TTP that has served as a template for other non- randomized studies performed successfully in Europe. He is continuing his research work in TTP as a site PI for caplacizumab, a novel heavy chain monoclonal antibody that blocks VonWillebrand A1domain-platelet receptor Ib binding. He is also pursuing therapies for other thrombotic microangiopathies, such as “TAMOF”, or Thrombocytopenia-associated Multiorgan Failure, with plans for designing a randomized pilot trial utilizing plasma exchange.
Clinical Interest
Dr. Kiss also has been active in studying factors associated with the development of iron-deficiency and the effectiveness of low dose iron supplementation for this condition, utilizing blood donors as a research model. He served as a coinvestigator and leader of the laboratory substudy on the REDS-II Iron Study Evaluation (RISE), a multicenter observational study that redefined the prevalence of and risk factors for iron deficiency in US blood donors. This trial led to the pivotal Hemoglobin and Iron Recovery Study (HEIRS), a randomized controlled trial of low dose iron supplementation in blood donors. The primary results of this study were published in JAMA in 2015. Several ancillary studies are now being analyzed and prepared for publication, including a study quantifying iron compartments in blood donors and a study of iron biomarkers, including hepcidin and erythropoietin in relation to iron and hemoglobin recovery. In addition, Dr. Kiss has served as the site-PI on the STRIDE-Strategies to Reduce Iron Deficiency study, which tested several operational approaches to improve the compromised iron status of blood donors, including measurement and notification of ferritin levels and the use of two different iron formulations taken over a two year period of regular blood donation. Ancillary operational and iron quantification studies are also being published in relation to this trial.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Raval JS, Padmanabhan A, Kremer Hovings JA, Kiss JE. Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. American Journal of Hematology. 2015; 90(1): E22doi:10.1002.
Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, Kleinman SH, Cable RG. Oral iron supplementation after blood donation: a randomized clinical trial. Journal of the American Medical Association. 2015; 313(6): 575-83.
Kiss JE. Thrombotic Thrombocytopenic Purpura. Conn's Current Therapy. 2014; 878-81.
Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM, Winters JL. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. Journal of Clincial Apheresis. 2013; Epub ahead of print.
Kiss JE, Steele WR, Wright DJ, Mast AE, Carey PM, Murphy EL, Gottschall JL, Simon TL, Cable RG. NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Laboratory variables for assessing iron deficiency in REDS-II Iron Status Evaluation (RISE) blood donors. Transfusion. 2013; Epub ahead of print.
Qu L, Kiss JE, Dargo G, Carcillo JA. Outcomes of previously healthy pediatric patients with fulminant sepsis-induced multisystem organ failure receiving therapeutic plasma exchange. Journal of Clinical Apheresis. 2011; 26: 208-13.
Kiss JE. Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. International Journal of Hematology. 2010; 91: 36-45.
Nguyen TC, Yong YH, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J, Carcillo JA. Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Critical Care Medicine. 2008; 36: 1-9.
George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. Journal of Clinical Apheresis. 2006; 21: 49-56.
Bennett CL, Kiss JE. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet. 1998; 352: 1036-7.